genetic diseases

A chessboard with blocks that read MA

Pharma

Neurocrine pays $2.9B for Soleno, its largest M&A deal ever

The acquisition of Soleno and its hyperphagia drug Vykat XR comes a few months after Neurocrine unveiled an obesity pipeline.

Angus Liu Apr 6, 2026 10:30am

Darts failing to hit bullseye

Rhythm's Imcivree posts ph. 3 miss in rare genetic obesities

Mar 17, 2026 11:43am

opening door to brick wall

Fierce Biotech

Senate hearing takes aim at FDA's rare disease review process

Feb 26, 2026 3:50pm

failure crash no fail rocket cancelled end

Quince explores options after ph. 3 rare disease flop

Jan 30, 2026 10:44am

arrow bullseye target on target

Arrowhead strikes true with first FDA approval

Nov 18, 2025 3:44pm

FDA

FDA approves Soleno's Vykat XR for insatiable hunger disorder

Mar 27, 2025 11:24am